«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2022 06

Page:

1023-1027

Research Field:

Publishing date:

Info

Title:

Establishment and validation of a nomogram to predict cancer-specific survival for patients with inflammatory breast cancer based on SEER database

Author(s):

HUANG Yajing¹; WU Hao²; CHEN Yan¹; LI Xingrui¹

1.Department of Thyroid and Breast Surgery;2.Department of General Surgery,Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology,Hubei Wuhan 430030,China.

Keywords:

inflammatory breast cancer; prognosis; SEER; nomogram

PACS:

R737.9

DOI:

10.3969/j.issn.1672-4992.2022.06.014

Abstract:

Objective:To establish a risk model to predict inflammatory breast cancer (IBC) survival.Methods:The cases diagnosed as IBC from 2010 to 2015 were screened using Surveillance,Epidemiology and End Results (SEER) database.Univariate and Logistic multivariate regression analysis were performed to identify the independent risk factors related to IBC survival and further establish a nomogram to predict 1-,3-,and 5-year cancer-specific survival (CSS) of IBC patients.Harrell's C-index and calibration curve were used to validate the nomogram.Results:A total of 2 754 IBC cases that met the inclusion criteria were screened out,and 1 933 cases were randomly selected as the training set and 821 cases were selected as validation set.Univariate and multivariate analyses showed that age,race,histological grade,N stage,M stage,breast subtype,surgery,radiotherapy and chemotherapy were independent risk factors significantly associated CSS.The internally and externally validated Harrell's C-indexes were 0.731 (95%CI:0.714~0.749) and 0.752 (95%CI:0.777~0.727).The calibration curve showed that the prediction fits well for the 1-,3-,and 5-year CSS.Conclusion:Age,race,histological grade,N stage,M stage,breast subtype,surgery,radiotherapy and chemotherapy are independent risk factors affecting the survival of IBC patients.The nomogram constructed based on the risk factors can better evaluate the survival of IBC patients individually.

References:

[1] ROBERTSON FM,BONDY M,YANG W,et al.Inflammatory breast cancer:the disease,the biology,the treatment［J］.CA Cancer J Clin,2010,60(6):351-375.
[2] DESANTIS CE,MA J,GAUDET MM,et al.Breast cancer statistics,2019［J］.CA Cancer J Clin,2019,69(6):438-451.
[3] ROSENBLUTH JM,OVERMOYER BA.Inflammatory breast cancer:a separate entity［J］.Curr Oncol Rep,2019,21(10):86.
[4] MENTA A,FOUAD TM,LUCCI A,et al.Inflammatory breast cancer:what to know about this unique,aggressive breast cancer［J］.Surg Clin North Am,2018,98(4):787-800.
[5] DO NASCIMENTO VC,RAJAN R,REDFERN A,et al.Inflammatory breast cancer:A decade of experience［J］.Asia Pac J Clin Oncol,2016,12(3):242-247.
[6] FERNANDEZ SV,MACFARLANE AWT,JILLAB M,et al.Immune phenotype of patients with stage IV metastatic inflammatory breast cancer［J］.Breast Cancer Res,2020,22(1):134.
[7] SOBIN LH,COMPTON CC.TNM seventh edition:what's new,what's changed:communication from the International Union Against Cancer and the American Joint Committee on Cancer［J］.Cancer,2010,116(22):5336-5339.
[8] RUETH NM,LIN HY,BEDROSIAN I,et al.Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer:an analysis of treatment and survival trends from the National Cancer Database［J］.J Clin Oncol,2014,32(19):2018-2024.
[9] LAMB CC,EBERLEIN TJ,PARKER LM,et al.Results of radical radiotherapy for inflammatory breast cancer［J］.Am J Surg,1991,162(3):236-242.
[10] YOULAND RS,FINLEY RR,PETERSEN IA,et al.Multi-isocenter hybrid electron and rapid arc photon treatment for reirradiation of extensive recurrent inflammatory breast cancer［J］.Med Dosim,2017,42(4):363-367.
[11] KIM R,OSAKI A,TOGE T.Current and future roles of neoadjuvant chemotherapy in operable breast cancer［J］.Clin Breast Cancer,2005,6(3):223-232.
[12] CRISTOFANILLI M,BUCHHOLZ TA.Proceedings of the first international inflammatory breast cancer conference［J］.Cancer,2010,116(11 Suppl):2729.
[13] LIU J,CHEN K,JIANG W,et al.Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation:an analysis from the National Cancer Database［J］.J Cancer Res Clin Oncol,2017,143(1):161-168.
[14] VAN UDEN DJ,VAN LAARHOVEN HW,WESTENBERG AH,et al.Inflammatory breast cancer:an overview［J］.Crit Rev Oncol Hematol,2015,93(2):116-126.
[15] DOBBS J,KRISHNAMURTHY S,KYRISH M,et al.Confocal fluorescence microscopy for rapid evaluation of invasive tumor cellularity of inflammatory breast carcinoma core needle biopsies［J］.Breast Cancer Res Treat,2015,149(1):303-310.
[16] LIM B,WOODWARD WA,WANG X,et al.Inflammatory breast cancer biology:the tumour microenvironment is key［J］.Nat Rev Cancer,2018,18(8):485-499.
[17] CHENG YC,SHI Y,ZHANG MJ,et al.Long-term outcome of inflammatory breast cancer compared to non-inflammatory breast cancer in the setting of high-dose chemotherapy with autologous hematopoietic cell transplantation［J］.J Cancer,2017,8(6):1009-1017.

Memo

Memo:

湖北省科技计划项目（编号：2019CFB662）

Common functions

Last Update: 1900-01-01